NUCLEAR THEME — GOLDEN GROUND TRUTH
2026-04-22 11:42 · 73.7 KB
Compiled from all existing DD, reports, and data as of 2026-04-22
MACRO CONTEXT
Japan has 15 operating reactors out of 32 operable, with the 7th Strategic Energy Plan targeting 20% nuclear by FY2040. The $40B US-Japan BWRX-300 SMR deal (Mar 2026) and data center power demand tripling by 2034 are accelerating restarts. NRA eased anti-terrorism deadlines (Apr 2026). 60+ year reactor lifetime extensions approved. European SMR momentum accelerating: Rolls-Royce SMR signed landmark UK contract with GBE-N for 3 SMRs at Wylfa (Apr 13, 2026; £599M govt loan); GVH-AFRY collaboration for BWRX-300 in Sweden (Apr 7, 2026); Swiss Council of States voted to lift nuclear ban (Mar 2026). Japanese supply chain companies positioned as critical global suppliers.
RECENT UPDATES
- 2026-04-21 (evolve): Full financial cross-validation of all 14 nuclear stocks using StockAnalysis data. Organo best financials (ROE 23.5%, OpMar 21.4%). JSW strongest moat (80% global forgings). Yokogawa best risk/reward (Fwd PE 20.4, D/E 0.05). Kobe Steel/Kanadevia/Stella downgraded to LOW on poor fundamentals.
Stocks: 6368.T, 7013.T, 5631.T, 6841.T, 6504.T, 6492.T, 6501.T, 6370.T, 5310.T, 6302.T, 7004.T, 5406.T, 6361.T, 4888.T
- 2026-04-21 (explore): T-glass method applied to nuclear: found 9 missing companies. Added 5 to JSON: Toyo Tanso (HTGR graphite MONOPOLY), Okano Valve (BWR safety valve MONOPOLY), Kobe Steel (RPV duopoly), Ebara (NuScale pumps), Stella Pharma (BNCT drug MONOPOLY).
Stocks: 5310.T, 6492.T, 5406.T, 6361.T, 4888.T
- 2026-04-16 (evolve): European SMR momentum: GBE-N/Rolls-Royce Wylfa contract (Apr 13, £599M loan), GVH-AFRY Sweden BWRX-300 (Apr 7), Swiss nuclear ban lift vote (Mar). Yokogawa DPCS moves to active design phase. JSW/Hitachi European pipeline expanded.
Stocks: 6841.T, 5631.T, 6501.T
- 2026-04-14 (evolve): Updated 3 stocks: JSW fwd PE corrected, Yokogawa dividend raised ¥64→¥78, Organo FY2024 earnings +39.5% confirmed
Stocks: 5631.T, 6841.T, 6368.T
- 2026-04-19 (evolve): Deep evolve: Fuji Electric (6504.T) — FY26 guidance raised, Bosch SiC JV, nuclear I&C still 95% monopoly.
Stocks: 6504.T
ALL COMPANIES (14 stocks)
| # | Ticker | Name | Conv | Weight | PE | Fwd PE | PB | ROE | OpMar | D/E | Yield | Mkt Cap | Nuclear% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 7013.T | IHI Corporation | HIGH | 12.5% | 27.6 | 26.8 | 5.65 | 23.6% | 9.1% | 108% | 0.64% | ¥3.34T | est |
| 2 | 6501.T | Hitachi | MEDIUM | 6.2% | 28.5 | 27.2 | 3.54 | 13% | 11.1% | 16% | 0.89% | ¥23.2T | est |
| 3 | 5631.T | Japan Steel Works | HIGH | 15.6% | 32.7 | 31.1 | 3.28 | 10.5% | 8.4% | 34% | 1.02% | ¥670B | est |
| 4 | 6841.T | Yokogawa Electric | HIGH | 14.6% | 24.2 | 20.4 | 2.72 | 12.2% | 14.6% | 5% | 1.18% | ¥1.40T | est |
| 5 | 6504.T | Fuji Electric | MEDIUM | 8.3% | 20.3 | 17.7 | 2.19 | 11.8% | 10.3% | 13% | 1.52% | ¥1.74T | est |
| 6 | 7004.T | Kanadevia | LOW | 3.1% | 19.8 | 14.2 | 1.1 | 5.8% | 2.0% | 88% | 2.08% | ¥210B | est |
| 7 | 6368.T | Organo Corporation | HIGH | 15.6% | 25.2 | 23.3 | 5.43 | 23.5% | 21.4% | 24% | 1.20% | ¥710B | est |
| 8 | 6370.T | Kurita Water Industries | MEDIUM | 5.2% | 38.4 | 21.8 | 2.53 | 6.8% | 13.7% | 32% | 1.39% | ¥890B | est |
| 9 | 6302.T | Sumitomo Heavy Industries | MEDIUM | 4.2% | 20.6 | 18.8 | 0.92 | 4.7% | 4.8% | 37% | 2.83% | ¥630B | est |
| 10 | 5310.T | Toyo Tanso | MEDIUM | 5.2% | 23.2 | 23.8 | 1.3 | 5.7% | 14.6% | 6% | 2.42% | ¥127B | est |
| 11 | 6492.T | Okano Valve | MEDIUM | 4.2% | 21.6 | None | 1.77 | 8.2% | 10.1% | 5% | 0.41% | ¥21.2B | est |
| 12 | 5406.T | Kobe Steel | LOW | 2.1% | 8.7 | 8.5 | 0.59 | 7.2% | 4.8% | 65% | 4.14% | ¥761B | est |
| 13 | 6361.T | Ebara | LOW | 2.1% | 30.9 | 25.4 | 4.49 | 15.8% | 12.1% | 43% | 1.34% | ¥2.34T | est |
| 14 | 4888.T | Stella Pharma | LOW | 1.0% | None | None | 9.04 | -9.8% | -23.6% | 29% | 0% | ¥24.4B | est |
7013.T — IHI Corporation
Thesis: Japan's most direct SMR supply chain play: X-energy partnership (Mar 2026) positions IHI to supply fabricated nuclear components into the US market. NuScale investor ($20M) and preferred manufacturer. Aero engine segment (GE/P&W JVs) provides high-margin earnings base while nuclear optionality is largely unpriced.
Risk: SMR timelines uncertain. Stock +145% in 52 weeks — good news may be priced in. Aero segment exposed to PW1100G engine inspection costs.
Trigger: If X-energy or NuScale reach construction milestones, increase. If stock corrects >20%, consider adding.
Supply Chain:
- X-energy: SMR component fabrication (confirmed) [https://x-energy.com/news/x-energy-ihi-corporation-partner-to-advance-u-s-japan-smr-supply-chain-development/]
- NuScale Power: SMR preferred manufacturer (confirmed) [https://www.nuscalepower.com/press-releases/2021/nuscale-secures-investment-support-for-smr-deployment-from-ihi-corporation]
- GE Vernova: Aero engine JV partner (confirmed) [https://www.ihi.co.jp/en/]
- Japanese nuclear utilities: Reactor vessels, containment (probable)
Key Dates:
- 2026-05-08: Earnings announcement for IHI Corporation
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-08: If X-energy or NuScale reach construction milestones, increase. If stock corrects >20%, consider add
6501.T — Hitachi
Thesis: Holds the most commercially advanced SMR asset globally through GE Hitachi Nuclear Energy (50/50 JV) developing the BWRX-300 — the only SMR with contracted projects (Canada, Poland, US). $40B Japan-US deal earmarks tens of billions for GEH reactors. European pipeline expanding: GVH-AFRY collaboration (Apr 7, 2026) for BWRX-300 deployment in Sweden incl. SSM licensing support; Swiss parliament vote to lift nuclear ban (Mar 2026) opens another potential market. Digital segment provides growth while nuclear is the optionality.
Risk: Nuclear is a small sub-segment of a ¥10T conglomerate — limited direct earnings leverage. Large-cap (¥21.6T) means nuclear catalysts move the needle slowly.
Trigger: Watch BWRX-300 construction progress at Darlington (Canada). If first SMR connects to grid, major re-rating catalyst.
Supply Chain:
- GE Vernova (50/50 JV): BWRX-300 SMR development and deployment (confirmed) [https://www.gevernova.com/nuclear/carbon-free-power/bwrx-300-small-modular-reactor]
- Ontario Power Generation (Canada): BWRX-300 reactor (confirmed) [https://www.canada.ca/en/nuclear-safety-commission/news/2025/04/commission-authorizes-ontario-power-generation-inc-to-construct-1-bwrx-300-reactor-at-the-darlington-new-nuclear-project-site.html]
- SaskPower (Canada): BWRX-300 reactor (confirmed) [https://www.gevernova.com/nuclear/carbon-free-power/bwrx-300-small-modular-reactor]
- Southeast Asian utilities: BWRX-300 exploration (probable)
- AFRY (Sweden): BWRX-300 European deployment engineering (confirmed) [https://afry.com/en/newsroom/press-releases/afry-and-ge-vernova-hitachi-signs-collaboration-agreement-deploy-bwrx-300]
Key Dates:
- 2026-05-09: Earnings announcement for Hitachi
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-09: Watch BWRX-300 construction progress at Darlington (Canada). If first SMR connects to grid, major re
- 2026-08-01: Swiss parliament final vote on nuclear ban lift — opens new European market for BWRX-300
5631.T — Japan Steel Works
Thesis: Near-monopoly on ultra-large nuclear-grade steel forgings (reactor pressure vessels, steam generator shells). Only manufacturer globally with this capability. Backlog >¥135B. METI confirmed as BWRX-300 supplier. ¥28B CAPEX for SMR capacity expansion. Targeting 200+ rotor shafts by FY2028 (50% increase from FY2025). 18-month manufacturing cycle = multi-year visibility. 9-month FY2025 profit lifted, full-year guidance maintained (Feb 2026). European BWRX-300 pipeline expanding: GVH-AFRY Sweden deployment (Apr 2026), Poland 24-unit program, plus Swiss ban lift opens long-term demand. Every new BWRX-300 site = JSW forging order given ~130 RPVs in service globally.
Risk: FCF turned negative (-¥19.7B) in FY2025 due to capex ramp. PE ~35x on negative cash flow is expensive. Industrial machinery segment exposed to weak China demand. Stock +78% in 52 weeks — valuation stretched.
Trigger: If operating CF turns positive in May 8 earnings, increase to 20%. If negative for second year, reduce to 12%. Watch rotor shaft delivery pipeline for FY2028 target progress.
Supply Chain:
- GE Hitachi / BWRX-300: Reactor pressure vessel forgings (confirmed) [https://world-nuclear.org/information-library/nuclear-power-reactors/other/heavy-manufacturing-of-power-plants]
- Westinghouse / AP1000: RPV and steam generator forgings (probable)
- Japanese nuclear utilities: Replacement forgings for restarts (probable)
Key Dates:
- 2026-05-08: FY2025 full-year earnings — key test for operating CF turnaround
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-08: If operating CF turns positive, increase to 20%. If negative for second year, reduce to 12%.
6841.T — Yokogawa Electric
Thesis: Signed exclusive DPCS contract with Rolls-Royce SMR (Feb 2, 2026) for global fleet control systems — UK + Czech Republic delivery confirmed. CENTUM VP is the standard DCS platform for Japanese nuclear plants. Near-zero D/E (5%), 14.6% op margin, ROIC ~19%. Dividend raised to ¥78/share for FY2026. Highest quality business in the nuclear group. MAJOR CATALYST: GBE-N signed landmark contract with Rolls-Royce SMR (Apr 13, 2026) to begin 3 SMRs at Wylfa, Wales — £599M govt loan secured. This moves Yokogawa's DPCS from 'contract signed' to 'active design phase' with long lead-time equipment ordering now underway.
Risk: Nuclear I&C is a small share of total revenue — incremental earnings impact from SMR contract in early years. Stock +107% in 52 weeks. P/E 24.7x above JP Electronic industry average of 15.5x.
Trigger: GBE-N contract signed Apr 13 — watch for Yokogawa long lead-time equipment orders and Wylfa site preparation milestones. May 12 earnings for nuclear I&C order book impact from GBE-N deal. If P/E expands >30x without earnings growth, trim.
Supply Chain:
- Rolls-Royce SMR / GBE-N: DPCS for global SMR fleet (confirmed) [https://www.yokogawa.com/ca/news/press-releases/2026/2026-02-02]
- Saudi Aramco: CENTUM VP DCS + AI control agents (confirmed) [https://www.yokogawa.com/us/news/press-releases/2025/2025-10-29]
- Shell: Robotics + AI plant maintenance (confirmed) [https://www.yokogawa.com/news/press-releases/2025/2025-06-18]
- ADNOC: ICSS, ESD, fire & gas systems (confirmed) [https://adnoc.ae/en/news-and-media/press-releases/2025/adnoc-signs-aed6-billion-framework-agreements-to-manufacture]
- Japanese nuclear utilities: CENTUM VP DCS for reactor control (probable)
Key Dates:
- 2026-05-12: FY2025 earnings + nuclear I&C order book update
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-12: GBE-N contract signed Apr 13 — watch for Yokogawa equipment orders and Wylfa site milestones. If P/E >30x without earnings growth, trim.
- 2026-04-13: GBE-N signed landmark contract with Rolls-Royce SMR for 3 units at Wylfa — moves Yokogawa DPCS to active design phase
6504.T — Fuji Electric
Thesis: 95% domestic share in nuclear radiation monitoring + top-5 global IGBT/SiC. Oct 2025 raised FY26 guidance (sales ¥1,185B, OP ¥128.5B, NI ¥89B) + interim dividend ¥91 (+21% YoY). Dec 2025 Bosch SiC co-development agreement for package-compatible EV inverter modules. Capex ¥200B over FY24-26 driving 50x SiC capacity increase vs 2022 baseline.
Risk: J-Quants PE 27.3x vs StockAnalysis 20.6x — methodology gap (J-Q annualizes cumulative EPS). ROE on latest J-Q filing dipped to 8.2% from 11.8% prior. SiC competition (Rohm, Infineon, STMicro) intensifying. Nuclear I&C is a fraction of Energy segment — not standalone driver.
Trigger: FY25 full-year results May 12, 2026. If SiC capacity ramp below 50x target OR Bosch JV slips past 2027, trim. If data-center power electronics orders break out (¥50B+ quarterly run-rate), upgrade to Core weight.
Supply Chain:
- JNFL Rokkasho: 300-channel radiation monitoring panel (confirmed) [https://www.fujielectric.com/products/radiation/]
- Honda: 14-in-1 IGBT power module for Accord Hybrid (confirmed) [https://chargedevs.com/features/pushing-the-power-limits-fuji-electric-on-the-new-requirements-of-power-electronics/]
- Robert Bosch: Package-compatible SiC power modules for EV inverters (confirmed) [https://www.fujielectric.com/about/notice/detail/1205558_5359.html]
- Vestas Wind Systems: Large-capacity IGBT modules for wind turbines (confirmed) [https://www.fujielectric.com/about/stories/detail/1203095_5365.html]
- J-Power / Kansai Electric / TEPCO: Nuclear I&C and radiation monitoring systems (confirmed) [https://www.fujielectric.com/products/radiation/]
Key Dates:
- 2026-05-12: FY25 full-year results (fiscal Mar-end)
- 2026-05-12: SiC/IGBT segment backlog and nuclear I&C order flow
- 2026-06-30: Semiannual portfolio rebalance
- 2026-08: Q1 FY26 results
- 2026-10: Interim dividend announcement — watch for payout ratio progress toward 30%
- 2026-12: Bosch SiC JV first package-compatible module samples expected
7004.T — Kanadevia
Thesis: Only pure-play spent nuclear fuel logistics company on TSE. 40+ year track record in transport/storage casks (since 1978). TEPCO JV for Fukushima decommissioning. US subsidiary NAC International provides dollar-denominated revenue. Decarbonization segment rebranding captures ESG capital.
Risk: Negative FCF (-¥12.8B) and high D/E (0.88). Low op margin (2%). Contract slippage risk on EPC projects.
Trigger: If D/E exceeds 1.0 or FCF negative 2+ more periods, cut to 5%. If TEPCO JV ships first cask, increase.
Supply Chain:
- TEPCO: Fukushima decommissioning casks (Toso Mirai JV) (confirmed) [https://www.tepco.co.jp/en/hd/newsroom/press/archives/2022/20221020_01.html]
- US nuclear utilities (via NAC International): Spent fuel transport/storage casks (confirmed) [https://www.nacintl.com/about-us/kanadevia-corporation]
- Deep Isolation: Deep borehole nuclear waste disposal (probable)
Key Dates:
- 2026-05-14: Earnings announcement for Kanadevia
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-14: If D/E exceeds 1.0 or FCF negative 2+ more periods, cut to 5%. If TEPCO JV ships first cask, increas
6368.T — Organo Corporation
Thesis: Near-monopoly on BWR condensate water treatment in Japan — IFD technology adopted in ALL BWR condensate demineralizer vessels. Every reactor restart = direct Organo revenue. Best quality in nuclear group: ROE 18.4%, op margin 21.4%, revenue +8.6% YoY. FY2024 earnings +39.5% growth confirmed (March 30, 2026). Also serves semiconductor fabs (TSMC Kumamoto confirmed). Stock +178% in 1Y reflects strong execution.
Risk: PE 26x and PB 5.6x are expensive after +178% 1Y run. Forward PE 24x offers limited margin of safety. Revenue concentration in Japan nuclear + semiconductor could be cyclical.
Trigger: If PB expands >7x without earnings support, trim. Watch each reactor restart announcement — direct revenue event. May earnings for FY2025 guidance on nuclear vs semiconductor mix.
Supply Chain:
- All Japanese BWR operators: IFD condensate demineralizers (monopoly) (confirmed) [https://www.organo.co.jp/english/business/energy/]
- TSMC Kumamoto (JASM): Ultrapure water systems (confirmed) [https://asia.nikkei.com/business/tech/semiconductors/tsmc-supplier-organo-aims-for-new-heights-after-tenfold-jump-in-stock]
- PWR operators (KEPCO, etc.): Makeup water, waste treatment (probable)
Key Dates:
- 2026-05-12: FY2025 earnings release + FY2026 guidance
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-12: If PB >7x without earnings support, trim. Watch each reactor restart — direct revenue.
6370.T — Kurita Water Industries
Thesis: Dual nuclear + semiconductor water chemistry exposure. Nuclear: coolant chemistry, corrosion inhibitors, radioactive waste minimization. Semiconductor: ultrapure water for Samsung/SK Hynix (confirmed) and TSMC Japan (probable). 16 consecutive years of dividend growth signals discipline.
Risk: Trailing PE 38x is stretched. ROE 6.8% is low. Depends on semiconductor + nuclear materializing simultaneously.
Trigger: If fwd PE expands >25x without earnings revision, trim to 5%.
Supply Chain:
- Samsung Electronics / SK Hynix: Ultrapure water chemicals for Korean fabs (confirmed) [https://www.kurita.co.jp/english/aboutus/press141209.html]
- Japanese nuclear utilities: Coolant chemistry programs, corrosion inhibitors (probable)
- TSMC Japan fabs: Ultrapure water systems (probable)
Key Dates:
- 2026-05-09: Earnings announcement for Kurita Water Industries
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-09: If fwd PE expands >25x without earnings revision, trim to 5%.
6302.T — Sumitomo Heavy Industries
Thesis: Only company with confirmed ITER fusion cryocooler contracts — world's largest cryocooler manufacturer. Also sole Japanese PET cyclotron maker (100+ deliveries) and world-first BNCT cancer treatment (NeuCure). Trading at 0.92x book is a value anomaly given the cryocooler technology moat.
Risk: Nuclear/fusion is a minority of revenue. Low ROE (4.7%) and margins (4.8%) from industrial machinery segments dilute returns.
Trigger: Track BNCT installation announcements and ITER construction milestones. If no progress in 12 months, reduce to 5%.
Supply Chain:
- ITER Organization: Cryocoolers for fusion reactor cryogenic system (confirmed) [https://www.shi.co.jp/english/products/mechatronics/cold/index.html]
- KEK (J-PARC): Cryocoolers for particle accelerators (confirmed) [https://www.shi.co.jp/english/products/mechatronics/cold/index.html]
- GE HealthCare / Siemens MRI: Cryocoolers for MRI superconducting magnets (probable)
Key Dates:
- 2026-05-12: Earnings announcement for Sumitomo Heavy Industries
- 2026-06-30: Semiannual portfolio rebalance
- 2026-05-12: Track BNCT installation announcements and ITER construction milestones. If no progress in 12 months,
5310.T — Toyo Tanso
Thesis: MONOPOLY: Only supplier of IG-110 nuclear-grade graphite used in ALL HTGRs globally (Japan HTTR, China HTR-PM, X-energy Xe-100). $40M X-energy supply agreement. No substitute exists. Micro-cap with massive leverage to SMR/HTGR buildout.
Risk: HTGR commercialization timeline uncertain. Small revenue base. Xe-100 construction delays would push out revenue.
Trigger: X-energy Xe-100 construction milestones. HTGR orders from other countries.
Supply Chain:
- X-energy: IG-110 graphite for Xe-100 HTGR fuel pebbles (confirmed) [https://x-energy.com/media/news-releases/x-energy-toyo-tanso-announce-graphite-supply-agreement]
6492.T — Okano Valve
Thesis: MONOPOLY: Main Steam Safety Relief Valve (MS-SRV) installed in ALL BWR plants in Japan. World-first stellite overlay technology. Micro-cap (16B) = huge leverage to nuclear restarts.
Risk: Tiny company, low liquidity. BWR restart pace is the sole catalyst.
Trigger: BWR restart schedule (Kashiwazaki-Kariwa, Onagawa, Shika).
5406.T — Kobe Steel
Thesis: Only company globally self-sufficient in ALL RPV materials: forged shells + heavy steel plates + welding materials. Duopoly with JSW in nuclear forgings. ~250B nuclear revenue.
Risk: Altman Z-Score 1.78 (distress zone). Heavy debt D/E 0.65. Thin margins 4.8%. 2017 data fraud scandal. Nuclear is only ~2-4% of revenue — NOT a nuclear play, it is a steel conglomerate.
Trigger: Nuclear new-build orders. BWRX-300 component contracts.
6361.T — Ebara
Thesis: Nuclear coolant pump supplier since 1973. NuScale SMR steam compressor partnership (Mar 2026). Large-cap diversified but nuclear is a growing catalyst.
Risk: PE 30.9x after +165% run — valuation stretched. Nuclear is only ~5-8% of revenue. Primarily a semiconductor equipment play (46% of revenue). Cycle risk.
Trigger: NuScale TVA construction progress. New pump orders.
Supply Chain:
- NuScale Power: Steam compressor for SMR (confirmed) [https://www.nuscalepower.com/press-releases/2026/nuscale-power-and-ebara-elliott-energy]
4888.T — Stella Pharma
Thesis: World ONLY producer of pharmaceutical-grade boron drug (Steboronin) for BNCT cancer therapy. Japan is 5+ years ahead of any country. Micro-cap (12B), speculative but truly unique monopoly.
Risk: Loss-making biotech. PB 9x for money-losing company. Share dilution +4.1% YoY. BNCT adoption extremely slow. Speculative call option only.
Trigger: BNCT treatment volume growth. International regulatory approvals.
REPORT: nuclear_dd_evolution_2026-04-14.md
Nuclear Theme DD Evolution — 2026-04-14
Time: 11:42
Type: Scheduled DD evolution (update existing reports)
Stocks updated: 5631.T, 6841.T, 6368.T (HIGH conviction, oldest data_date)
Data sources: J-Quants (paid plan), StockAnalysis.com, web search
Previous data_date: 2026-04-12 → Updated to: 2026-04-14
Changes Summary
| Ticker | Company | Key Changes | Thesis Status |
|---|---|---|---|
| 5631.T | Japan Steel Works | Earnings date corrected to May 8 (was May 12). Forward PE revised to 33.9x (was 34.3x). Added 200+ rotor shaft FY2028 target. ROE updated to 9.7% (was 10.5%). | HOLD — no thesis change |
| 6841.T | Yokogawa Electric | Dividend raised to ¥78/share (was ¥64). Div yield now 1.4% (was 1.1%). PE confirmed at 24.7x. | HOLD — thesis strengthened |
| 6368.T | Organo Corp | FY2024 earnings confirmed: +39.5% growth. ROE updated to 18.4% (was 23.5% — 3Q annualized vs full-year). PE confirmed at 26.1x. | HOLD — monitor valuation |
Cross-Validation Results
5631.T Japan Steel Works
| Metric | Previous (Apr 12) | J-Quants (Apr 14) | StockAnalysis | Final |
|---|---|---|---|---|
| PE trailing | 35.28 | 35.99 | 34.93 | 35.0 |
| Forward PE | 34.31 | 38.74 | 33.90 | 33.9 (SA analyst consensus) |
| PB | 3.53 | 3.50 | N/A | 3.50 |
| ROE | 10.5% | 9.72% | N/A | 9.7% |
| Op margin | 8.4% | 8.71% | 8.42% | 8.4% (SA confirmed) |
| Market cap | ¥724B | ¥717B | ¥717B | ¥717B |
News: Nikkei Asia reports JSW targeting 200+ rotor shaft deliveries by FY2028. 9-month FY2025 profit lifted, full-year guidance maintained (Feb 9, 2026). Earnings date confirmed May 8, 2026.
6841.T Yokogawa Electric
| Metric | Previous (Apr 12) | J-Quants (Apr 14) | StockAnalysis | Final |
|---|---|---|---|---|
| PE trailing | 24.82 | 23.93 | 24.66 | 24.7 |
| Forward PE | 20.73 | 24.03 | 20.60 | 20.6 (SA analyst consensus) |
| PB | 2.78 | 2.77 | N/A | 2.77 |
| ROE | 12.2% | 11.60% | N/A | 11.6% |
| Div yield | 1.1% | 1.39% | 1.14% | 1.4% (dividend raised to ¥78) |
| Market cap | ¥1.44T | ¥1.43T | ¥1.43T | ¥1.43T |
Dividend raised to ¥78/share for FY2026 (from ¥64). P/E above JP Electronic industry avg of 15.5x.
6368.T Organo Corporation
| Metric | Previous (Apr 12) | J-Quants (Apr 14) | StockAnalysis | Final |
|---|---|---|---|---|
| PE trailing | 26.42 | 30.63 | 26.08 | 26.1 (SA TTM full-year) |
| Forward PE | 24.47 | 27.23 | 24.16 | 24.2 |
| PB | 5.70 | 5.62 | N/A | 5.62 |
| ROE | 23.5% | 18.36% | N/A | 18.4% (3Q annualized) |
| Market cap | ¥745B | ¥735B | ¥735B | ¥735B |
FY2024 confirmed: Revenue ¥163B (+8.6%), NI ¥24.2B (+39.5%). ROE drop (23.5% → 18.4%) is 3Q annualization vs full-year TTM.
Errata
| Ticker | Metric | Original | Corrected | Source | Impact |
|---|---|---|---|---|---|
| 5631.T | Forward PE | 34.31 | 33.9 | StockAnalysis.com | Minor |
| 5631.T | Earnings date | 2026-05-12 | 2026-05-08 | Yahoo Finance | Date correction |
| 6841.T | Dividend | ¥64/share | ¥78/share | Yokogawa IR | Positive — yield up to 1.4% |
| 6368.T | ROE | 23.5% | 18.4% | J-Quants 3Q | Methodology difference |
| 6368.T | PE | 26.42 | 26.1 | StockAnalysis.com | Minor |
*Evolution performed 2026-04-14. Next evolution: 2026-04-16 or after May earnings.*
REPORT: nuclear_dd_validation_2026-04-13.md
Nuclear Theme DD Cross-Validation Report
Time: 09:55
Date: 2026-04-13
Data source date: 2026-04-12
Validation method: StockAnalysis.com statistics pages, WebSearch for news/developments
Stock prices as of: 2026-04-10 close (Tokyo)
Summary Table
| Ticker | Company | Issue | Severity | Finding |
|---|---|---|---|---|
| 7013.T | IHI Corp | Financials match | LOW | All metrics confirmed. PE 28.94, fwd PE 28.02, ROE 23.6%, op margin 9.1% all match StockAnalysis. X-energy MOU confirmed Mar 16 2026. |
| 7013.T | IHI Corp | NuScale risk elevated | MEDIUM | NuScale stock down 80% from peak, Q4 2025 disappointing, $507M accounting hit, project timelines pushed to 2033-34. IHI's $20M investment at risk. |
| 6501.T | Hitachi | ROE missing from source | LOW | StockAnalysis shows ROE "n/a" -- likely a reporting lag. PE 26.64, fwd PE 25.37, op margin 11.1% all confirmed. |
| 6501.T | Hitachi | BWRX-300 on track | LOW | Darlington construction proceeding on schedule (started May 2025, grid connection ~2030). SE Asia MOU signed Mar 2026. TVA US application under NRC review. |
| 5631.T | JSW | Negative FCF confirmed | MEDIUM | FCF -19.7B confirmed. PE 35.28, fwd PE 34.31 match. Op margin now 9.18% (report says 8.4%) -- slight improvement. 52-week gain +107%. |
| 5631.T | JSW | Valuation stretched | MEDIUM | EV/EBITDA 22.8x is very expensive for a cyclical industrial with negative FCF. FY2026E guidance: sales +16.7%, OP +7.3%. |
| 6841.T | Yokogawa | All metrics confirmed | LOW | PE 24.82, fwd PE 20.73, ROE 12.2%, op margin 14.6% all match. D/E 0.05 confirmed. Best quality in group. |
| 6841.T | Yokogawa | RR SMR catalyst advancing | LOW | Rolls-Royce SMR received UK regulatory justification Mar 25 2026. GDA Step 3 completing Aug 2026. First concrete possible 2027. Bullish for Yokogawa DPCS revenue. |
| 6504.T | Fuji Electric | All metrics confirmed | LOW | PE 19.62, fwd PE 17.13, ROE 11.8%, op margin 10.3% match. FY2026 OP guidance raised to 128.5B. |
| 7004.T | Kanadevia | Operating margin discrepancy | HIGH | Report says op margin 2.0%, but StockAnalysis shows 4.41% for FY2025. H1 FY2026 posted operating LOSS of -7.8B with net loss of -5.5B. Full-year OP forecast revised DOWN 33.2%. Earnings quality deteriorating. |
| 7004.T | Kanadevia | FCF improved but misleading | MEDIUM | StockAnalysis shows FCF -412M (report said -12.8B). Likely different periods. H1 operating loss suggests full-year FCF will be weak again. |
| 6368.T | Organo | All metrics confirmed | LOW | PE 26.42, fwd PE 24.47, ROE 23.5%, op margin 21.4% match. Revenue +9.7%, NI +34% YoY. |
| 6368.T | Organo | Valuation warning | MEDIUM | 52-week gain +202%. P/B 5.7x, P/S 4.25x are premium. EV/EBITDA 19.1x. Priced for perfection. |
| 6370.T | Kurita Water | All metrics confirmed | LOW | PE 38.22, fwd PE 21.67 match. ROE 6.8%, op margin 13.7% confirmed. Q3 FY2026 OP +22.2% YoY is positive. |
| 6370.T | Kurita Water | Trailing PE still elevated | MEDIUM | 38.2x trailing is expensive. Fwd PE 21.67 reflects earnings growth but still above monitoring trigger of 25x. |
| 6302.T | SHI | All metrics confirmed | LOW | PE 20.46, fwd PE 18.63, ROE 4.7%, op margin 4.8% all match. P/B 0.92 confirmed (below book). |
| 6302.T | SHI | BNCT overseas expansion | LOW | NeuCure BNCT system installing in China's Hainan Medical Tourism Pilot Zone, FY2025 start. Positive for thesis but small revenue. |
| ALL | All | Tariff risk | MEDIUM | US imposed 15% tariff on Japanese imports (reduced from 25%). Steel/aluminum/copper at 50%. Supreme Court struck down IEEPA-based tariffs (6-3). Uncertainty remains for nuclear equipment exports. |
Detailed Findings per Company
7013.T IHI Corporation
Price: 3,303 (Apr 10) | Market Cap: 3.50T | 52w Range: 1,378 - 4,698
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 28.94 | 28.94 | -- |
| Forward PE | 28.02 | 28.02 | -- |
| P/B | 5.92 | 5.92 | -- |
| ROE | 23.6% | 23.55% | -- |
| Op Margin | 9.1% | 9.07% | -- |
| D/E | 108% | 108% | -- |
| FCF | +68B | +68.3B | -- |
| Div Yield | 0.6% | 0.61% | -- |
Supply Chain Validation:
- X-energy MOU: CONFIRMED (Mar 16, 2026). Partnership to manufacture nuclear-grade components for Xe-100 HTGR. X-energy has 144-unit, 11 GW commercial pipeline. This is a stronger relationship than initially described -- not just MOU but component manufacturing assessment.
- NuScale: RISK ELEVATED. NuScale stock down ~80% from peak. Q4 2025 results disappointing. $507M accounting hit. Key project timeline pushed from 2030 to 2033-34. However, TVA/Entra1 6 GW framework provides long-term pipeline. IHI's $20M investment is small relative to 3.5T market cap.
- GE Vernova aero JV: No change, confirmed.
Material Changes: Strong turnaround from FY2024 loss (-68.2B) to FY2025 NI of 112.7B. Stock +145% in 52 weeks reflects this recovery. PEG 3.13 suggests growth priced in.
Verdict: MAINTAIN at MEDIUM conviction. NuScale headwinds offset by X-energy progress. Valuation is fair but not cheap after 145% run.
6501.T Hitachi
Price: 4,810 (Apr 10) | Market Cap: 21.64T | 52w Range: 3,008 - 6,039
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 26.64 | 26.64 | -- |
| Forward PE | 25.37 | 25.37 | -- |
| P/B | 3.30 | 3.30 | -- |
| ROE | N/A | N/A | -- |
| Op Margin | 11.1% | 11.12% | -- |
| D/E | 16% | 16% | -- |
| FCF | +1,390B | +1,394B | -- |
| Div Yield | 1.0% | 0.96% | -- |
Supply Chain Validation:
- GE Hitachi (GEH) BWRX-300: CONFIRMED and advancing. Darlington construction on schedule (May 2025 start, ~2029 completion, grid 2030). This is the most commercially advanced SMR globally.
- TVA Clinch River: CONFIRMED. NRC accepted and is reviewing construction application.
- Poland OSGE: CONFIRMED. Design development agreement signed Feb 24, 2026.
- SE Asia expansion: CONFIRMED. MOU signed Mar 2026 with GE Vernova.
- Sweden (Vattenfall): NEW. GEH/BWRX-300 is one of two finalists in Vattenfall's nuclear technology partner selection.
- AFRY (Sweden): NEW. Main Services Agreement signed Apr 2026 for BWRX-300 deployment support.
Material Changes: Pipeline expanding faster than expected. Multiple geographies (Canada, US, Poland, SE Asia, Sweden) de-risk single-project dependency. However, nuclear remains a small fraction of 21.6T conglomerate.
Verdict: MAINTAIN at MEDIUM conviction. BWRX-300 momentum is strong but diluted in mega-cap. Consider upgrading if Darlington reaches commissioning on schedule.
5631.T Japan Steel Works
Price: 9,836 (Apr 10) | Market Cap: 724B | 52w Range: 5,022 - 10,620
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 35.28 | 35.28 | -- |
| Forward PE | 34.31 | 34.31 | -- |
| P/B | 3.53 | 3.53 | -- |
| ROE | 10.5% | 10.54% | -- |
| Op Margin | 8.4% | 9.18% | +0.8pp |
| D/E | 34% | 34% | -- |
| FCF | -19.7B | -19.7B | -- |
| Div Yield | 0.9% | 0.94% | -- |
Supply Chain Validation:
- BWRX-300 forging supplier: Report says "METI confirmed." Unable to independently verify the specific METI confirmation via web search, but JSW's monopoly on single-piece RPV forgings is well-documented. Only manufacturer globally that can forge cores without welds.
- Westinghouse AP1000: Probable, unchanged.
- Domestic restart forgings: Probable, unchanged.
Material Changes:
- Operating margin improved to 9.18% (report said 8.4%) -- positive trend.
- FY2026E guidance: sales 290B (+16.7% YoY), OP 24.5B (+7.3%).
- EV/EBITDA 22.8x is the most expensive in the group on this metric.
- 28B CAPEX for SMR capacity expansion is driving the negative FCF. This is investment-phase spending, not operational deterioration.
- Steel/aluminum tariffs at 50% could impact if JSW exports forgings to US. Need to monitor.
Verdict: MAINTAIN at HIGH conviction but with caution flag. Monopoly position is real and irreplaceable. Negative FCF is investment-driven. But 35x PE on negative cash flow requires May 2026 earnings to show operating CF inflection. If CF stays negative, reduce per monitoring trigger.
6841.T Yokogawa Electric
Price: 5,637 (Apr 10) | Market Cap: 1.44T | 52w Range: 2,678 - 6,317
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 24.82 | 24.82 | -- |
| Forward PE | 20.73 | 20.73 | -- |
| P/B | 2.78 | 2.78 | -- |
| ROE | 12.2% | 12.22% | -- |
| Op Margin | 14.6% | 14.55% | -- |
| D/E | 5% | 5% | -- |
| FCF | +88B | +88.2B | -- |
| Div Yield | 1.1% | 1.14% | -- |
Supply Chain Validation:
- Rolls-Royce SMR DPCS: CONFIRMED and strengthened. Feb 2, 2026 contract covers design, validation, hardware, installation, commissioning. Delivered from UK (Runcorn), Czech Republic, and Netherlands. Yokogawa committed to "considerable investments" in UK nuclear supply chain.
- Rolls-Royce SMR UK progress: MAJOR CATALYST ADVANCING.
- GBE-N obtained Electricity Generation Licence (Mar 11, 2026)
- Rolls-Royce SMR received regulatory justification (Mar 25, 2026) -- first SMR in UK
- GDA Step 3 completing Aug 2026
- First concrete possible 2027, revenue service by 2031
- Czech Republic (CEZ): Up to 3 GW planned
- Sweden (Vattenfall): Final stage selection
- Saudi Aramco, Shell, ADNOC: No changes, all confirmed.
Material Changes: The Rolls-Royce SMR catalyst is materializing faster than expected. UK regulatory approvals in Q1 2026 are significant de-risking events. Yokogawa's DPCS is positioned for multi-geography revenue as RR SMR scales (UK + Czech + potentially Sweden). ROIC of 19.2% is best-in-class.
Verdict: MAINTAIN at HIGH conviction. Consider UPGRADE to top weighting. The RR SMR catalyst is no longer speculative -- regulatory approvals are landing. Quality metrics (ROE, ROIC, near-zero debt, 14.6% margin) are best in the portfolio. Forward PE 20.7x is reasonable for this quality.
6504.T Fuji Electric
Price: 11,395 (Apr 10) | Market Cap: 1.68T | 52w Range: 5,215 - 13,945
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 19.62 | 19.62 | -- |
| Forward PE | 17.13 | 17.13 | -- |
| P/B | 2.12 | 2.12 | -- |
| ROE | 11.8% | 11.82% | -- |
| Op Margin | 10.3% | 10.33% | -- |
| D/E | 13% | 13% | -- |
| FCF | +51B | +51.5B | -- |
| Div Yield | 1.6% | 1.60% | -- |
Supply Chain Validation:
- JNFL Rokkasho 300-channel panel: Confirmed via Fuji Electric product pages. Unchanged.
- 95% nuclear radiation monitoring share: Confirmed via Fuji Electric nuclear product pages. Every operating J-reactor is a customer.
- Honda IGBT: Confirmed, unchanged.
- Bosch SiC JV: Confirmed (Dec 2025 agreement).
- Vestas wind IGBT: Confirmed, unchanged.
Material Changes:
- FY2026 OP guidance RAISED to 128.5B -- positive signal.
- Revenue 1,183B (+4.3% YoY), NI 85.3B -- steady growth.
- Dual nuclear + power semiconductor exposure gives balanced risk.
- 52-week gain +114% but forward PE 17.1x is the most attractive valuation in the group.
- Kashiwazaki-Kariwa Unit 6 restart (Feb 2026) = direct revenue for radiation monitoring.
Verdict: MAINTAIN at HIGH conviction. Best risk/reward in the portfolio. Cheapest forward PE (17.1x), dual theme exposure, raised guidance, near-monopoly nuclear position. No changes needed.
7004.T Kanadevia
Price: 1,213 (Apr 10) | Market Cap: 204B | 52w Range: 774 - 1,228
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 19.62 | 19.62 | -- |
| Forward PE | 14.09 | 14.09 | -- |
| P/B | 1.09 | 1.09 | -- |
| ROE | 5.8% | 5.81% | -- |
| Op Margin | 2.0% | 4.41% | DISCREPANCY |
| D/E | 88% | 88% | -- |
| FCF | -12.8B | -412M | DISCREPANCY |
| Div Yield | 2.1% | 2.06% | -- |
KEY ISSUES:
1. Operating margin discrepancy: Report states 2.0%, StockAnalysis shows 4.41% for FY2025. The 2.0% may have been a TTM figure at a different point. However, H1 FY2026 (Apr-Sep 2025) posted an OPERATING LOSS of -7.8B and net loss of -5.5B. This is a severe deterioration.
2. FCF discrepancy: Report says -12.8B, StockAnalysis shows -412M for FY2025. Different measurement periods. Neither is encouraging.
3. Guidance slashed: Full-year FY2026 operating income forecast revised DOWN 33.2% to 18B. Reasons: fewer high-margin domestic Environment projects, Infrastructure business profitability decline, cost overruns.
4. Monitoring trigger hit: D/E at 0.88 is approaching the 1.0 cut threshold. FCF remains negative. The trigger says "If D/E exceeds 1.0 or FCF negative 2+ more periods, cut to 5%."
Supply Chain Validation:
- TEPCO Fukushima JV (Toso Mirai): Unable to find 2026 updates on cask shipments. The JV was announced Apr 2024, targeting FY2025 startup. No confirmation of first cask delivery found.
- NAC International (US subsidiary): Confirmed as wholly-owned, operational.
- Deep Isolation: Probable, unchanged.
Material Changes: Earnings quality is deteriorating significantly. H1 operating loss, guidance cut, and approaching D/E threshold are red flags.
Verdict: DOWNGRADE to LOW conviction. Reduce weight to 5%. Multiple monitoring triggers are flashing. H1 operating loss is a material negative. Wait for May 2026 earnings before re-evaluating. The nuclear decommissioning thesis is long-term valid but near-term execution is poor.
6368.T Organo Corporation
Price: 16,195 (Apr 10) | Market Cap: 745B | 52w Range: 5,220 - 18,260
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 26.42 | 26.42 | -- |
| Forward PE | 24.47 | 24.47 | -- |
| P/B | 5.70 | 5.70 | -- |
| ROE | 23.5% | 23.46% | -- |
| Op Margin | 21.4% | 21.38% | -- |
| D/E | 24% | 24% | -- |
| FCF | +19B | +18.8B | -- |
| Div Yield | 1.2% | 1.17% | -- |
Supply Chain Validation:
- BWR IFD condensate monopoly: Confirmed via JAIF Nuclear Industrial Directory listing for Organo. IFD technology in all Japanese BWR condensate vessels.
- TSMC Kumamoto (JASM): Confirmed, unchanged.
- Kashiwazaki-Kariwa Unit 6 restart (BWR, Feb 2026): DIRECT REVENUE EVENT. As a BWR restart, this triggers Organo's monopoly IFD business.
Material Changes:
- Revenue +9.7% YoY to 175.3B, NI +34% to 28.2B -- exceptional growth.
- 52-week gain +202% is extreme. Stock near 52-week high (18,260 high vs 16,195 current).
- P/B 5.7x, P/S 4.25x, EV/EBITDA 19.1x are all premium.
- Monitoring trigger: "If P/B expands >7x without earnings support, trim." Currently at 5.7x -- not yet triggered but approaching.
- Earnings are strong enough to justify current valuations (21.4% op margin, 23.5% ROE).
Verdict: MAINTAIN at HIGH conviction but tighten trim discipline. Fundamentals are excellent. BWR restart tailwind is real and confirmed by Kashiwazaki-Kariwa. However, +202% run requires strict valuation monitoring. Trim if P/B > 7x or if earnings growth decelerates.
6370.T Kurita Water Industries
Price: 8,118 (Apr 10) | Market Cap: 888B | 52w Range: 4,041 - 8,882
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 38.22 | 38.22 | -- |
| Forward PE | 21.67 | 21.67 | -- |
| P/B | 2.52 | 2.52 | -- |
| ROE | 6.8% | 6.79% | -- |
| Op Margin | 13.7% | 13.69% | -- |
| D/E | 32% | 32% | -- |
| FCF | +25B | +25B | -- |
| Div Yield | 1.4% | 1.38% | -- |
Supply Chain Validation:
- Samsung/SK Hynix Korea: Confirmed, unchanged.
- Japanese nuclear utilities: Probable, unchanged.
- TSMC Japan: Probable, unchanged.
Material Changes:
- Q3 FY2026 results: Sales 314.2B (+1.6% YoY), OP 40.2B (+22.2% YoY) -- strong profit growth despite modest revenue.
- 16 consecutive years of dividend growth -- confirmed.
- Monitoring trigger: "If fwd PE expands >25x without earnings revision, trim to 5%." Current fwd PE 21.67x -- WITHIN BOUNDS.
- PEG ratio 1.02 is the most attractive PEG in the group, suggesting growth-adjusted valuation is reasonable.
- Nuclear water chemistry exposure is real but hard to size as a standalone revenue contributor.
Verdict: MAINTAIN at MEDIUM conviction. Trailing PE 38x looks expensive but forward PE 21.7x and PEG 1.0 suggest earnings are accelerating. Q3 profit growth of +22.2% supports the thesis. Hold but trim if fwd PE crosses 25x.
6302.T Sumitomo Heavy Industries
Price: 5,266 (Apr 10) | Market Cap: 629B | 52w Range: 2,780 - 6,362
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 20.46 | 20.46 | -- |
| Forward PE | 18.63 | 18.63 | -- |
| P/B | 0.92 | 0.92 | -- |
| ROE | 4.7% | 4.67% | -- |
| Op Margin | 4.8% | 4.83% | -- |
| D/E | 37% | 37% | -- |
| FCF | +11B | +11.3B | -- |
| Div Yield | 2.8% | 2.75% | -- |
Supply Chain Validation:
- ITER cryocoolers: Confirmed via SHI Cryogenics Group product line. SHI is the world's largest cryocooler manufacturer with 50+ years experience. Specific ITER contract details not independently verified via web search but consistent with known procurement.
- KEK/J-PARC: Confirmed, unchanged.
- GE/Siemens MRI cryocoolers: Probable, unchanged.
- NeuCure BNCT: CONFIRMED expansion. First overseas installation in China's Hainan Medical Tourism Pilot Zone, FY2025 start. This validates the commercialization pathway.
Material Changes:
- P/B 0.92 (below book value) is the cheapest in the group. For a company with confirmed ITER contracts and BNCT commercialization, this is a value anomaly.
- Low margins (4.8%) and ROE (4.7%) from industrial machinery segments continue to dilute the high-quality niche businesses.
- BNCT China expansion is a new positive catalyst since last data update.
Verdict: MAINTAIN at MEDIUM conviction. Value case intact (below book, 2.75% yield). BNCT overseas expansion is positive. ITER/fusion remains long-term optionality. Low quality metrics (ROE, margin) prevent upgrade.
Macro Updates
NRA Reactor Restart Status
- 15 reactors now operating (up from 14 previously). Kashiwazaki-Kariwa Unit 6 (ABWR, 1,356 MW) restarted Feb 9, 2026 -- TEPCO's first restart since Fukushima.
- Kashiwazaki-Kariwa Unit 7 restart delayed to 2029-2030.
- Tokai-2 (JAPC): NRA approved, awaiting local consent through public dialogue sessions. Timeline uncertain.
- Tomari-3 (Hokkaido Electric): NRA approved Jul 2025, governor approved Dec 2025. Restart targeted "as early as possible in 2027" after seawall completion. Motivated by data center power demand.
- NRA eased anti-terrorism deadlines (Apr 2, 2026): Changed 5-year period start to when reactor begins operation, removing a key restart bottleneck.
- To reach 20% nuclear by FY2040, Japan needs ~27-30 reactors running. Currently at 15. Pace needs to roughly double.
7th Strategic Energy Plan
- Finalized Feb 18, 2025. Language shifted from "reducing dependence" to "maximum use of" nuclear energy.
- Nuclear target: ~20% of electricity by FY2040 (up from 8.5% in 2023).
- Renewables: 40-50% by 2040. Fossil fuels: 30-40%.
- Criticism: Plan described as "both unambitious and a fantasy" by Energy Tracker Asia. Achieving 20% requires 27+ reactors, but at current restart pace (~2/year), only ~24 by 2030.
- 60+ year lifetime extensions approved -- confirmed in plan.
SMR / BWRX-300 Developments
- Darlington (Canada): Construction proceeding on schedule. Started May 2025. First unit grid connection ~2030. Four units planned.
- TVA Clinch River (US): NRC accepted and reviewing construction application for first US BWRX-300.
- Poland (OSGE): Design development agreement signed Feb 24, 2026.
- Southeast Asia: GE Vernova + Hitachi MOU signed Mar 2026 to explore deployment.
- Sweden: GEH BWRX-300 is one of two finalists in Vattenfall's technology partner selection.
- Rolls-Royce SMR (UK): Regulatory justification received Mar 25, 2026. GDA completing Aug 2026. First concrete possible 2027.
- NuScale: Struggling. Stock down ~80%. Idaho CFPP terminated. Key project delayed to 2033-34. TVA/Entra1 6 GW framework is long-term positive.
- X-energy: Active. 11 GW pipeline, 144-unit orderbook. IHI partnership for Japanese component manufacturing.
Data Center Power Demand
- Japan data center electricity consumption projected to triple from 19 TWh (2024) to 57-66 TWh by 2034.
- Peak demand: 6.6-7.7 GW by 2034 = 4% of Japan's total peak load.
- Hokkaido Electric explicitly cited data center demand as motivation for Tomari-3 restart.
- $26B+ in hyperscaler investment committed to Japan (AWS, Google, Microsoft, Oracle).
- Nuclear seen as essential baseload to power AI/data center growth alongside renewables.
US Tariff Situation
- 15% reciprocal tariff on most Japanese imports (reduced from initial 25% proposal via US-Japan framework, Jul 2025).
- 50% tariff on steel, aluminum, copper under Section 232 -- could impact JSW nuclear forging exports.
- Supreme Court struck down IEEPA-based tariffs (6-3 ruling) -- may invalidate the 15% reciprocal tariff but enforcement timeline unclear.
- Japan's $550B investment pledge to US includes nuclear energy as strategic sector.
- Net impact on nuclear theme: Mixed. Tariffs could increase cost of Japanese nuclear components exported to US (IHI, JSW), but bilateral nuclear cooperation agreements may provide carve-outs. Domestic plays (Fuji Electric, Organo, Yokogawa) less exposed.
Recommendations
| Ticker | Company | Current Conviction | Recommendation | Rationale |
|---|---|---|---|---|
| 7013.T | IHI Corp | MEDIUM | MAINTAIN | X-energy advancing, NuScale struggling. Balanced risk. Wait for SMR construction milestones. |
| 6501.T | Hitachi | MEDIUM | MAINTAIN | BWRX-300 pipeline expanding across 5+ geographies. Nuclear diluted in mega-cap. On track. |
| 5631.T | JSW | HIGH | MAINTAIN with caution | Monopoly position is irreplaceable. May 2026 earnings must show CF inflection. 35x PE on negative FCF is a risk. |
| 6841.T | Yokogawa | HIGH | MAINTAIN / consider UPGRADE | RR SMR UK regulatory approvals landing. Best quality metrics in portfolio. DPCS revenue catalyst materializing. |
| 6504.T | Fuji Electric | HIGH | MAINTAIN | Best risk/reward. Cheapest forward PE (17.1x), raised guidance, dual theme. No action needed. |
| 7004.T | Kanadevia | MEDIUM | DOWNGRADE to LOW / reduce to 5% | H1 operating loss, guidance cut -33%, D/E approaching 1.0 threshold. Multiple monitoring triggers flashing. |
| 6368.T | Organo | HIGH | MAINTAIN with tight trim discipline | Excellent fundamentals but +202% run. Watch P/B vs 7x threshold. BWR restart tailwind is real. |
| 6370.T | Kurita Water | MEDIUM | MAINTAIN | Fwd PE 21.7x within bounds. PEG 1.0 is attractive. Q3 profit growth strong. Hold. |
| 6302.T | SHI | MEDIUM | MAINTAIN | Below-book value anomaly. BNCT China expansion is positive. Low quality metrics prevent upgrade. |
Portfolio Rebalance Actions (if implemented)
1. Reduce Kanadevia (7004.T) from 10% to 5%. Reallocate 5% to Yokogawa (6841.T) or Fuji Electric (6504.T).
2. Watch list for May 2026 earnings: JSW (CF inflection?), Kanadevia (further deterioration?), all companies (guidance updates).
3. Tariff exposure monitoring: IHI and JSW have US export exposure. Domestic plays (Fuji Electric, Organo, Yokogawa) are more insulated.
4. Next BWR restart events to watch: Tokai-2 (local consent pending), Tomari-3 (2027 target), Kashiwazaki-Kariwa Unit 7 (2029-30). Each is a direct revenue catalyst for Organo and Fuji Electric.
*Validation performed 2026-04-13. All financial metrics sourced from StockAnalysis.com statistics pages (S&P Global Market Intelligence data). News sourced via web search. Next validation recommended after May 2026 earnings season.*
REPORT: nuclear_full_comparison_2026-04-21.md
Nuclear Theme — Full 14-Stock Cross-Validation & Comparison
Time: 14:00
Date: 2026-04-21
Type: Evolve — full financial DD refresh + comparison across all stocks
Stocks: 14 (9 original + 5 new from T-glass method)
Data source: StockAnalysis.com (Apr 2026)
Complete Comparison Table
| # | Ticker | Company | Conv | Moat | PE | Fwd PE | PB | ROE% | OpMar% | D/E | Yield% | Nuc% | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6368.T | Organo | HIGH | ★★★★★ | 25.2 | 23.3 | 5.43 | 23.5 | 21.4 | 0.24 | 1.20 | 25-30 | 16/20 |
| 2 | 5631.T | Japan Steel Works | HIGH | ★★★★★ | 32.7 | 31.1 | 3.28 | 10.5 | 8.4 | 0.34 | 1.02 | 30-40 | 14/20 |
| 3 | 7013.T | IHI | HIGH | ★★★★ | 27.6 | 26.8 | 5.65 | 23.6 | 9.1 | 1.08 | 0.64 | 15-20 | 14/20 |
| 4 | 6841.T | Yokogawa Electric | HIGH | ★★★★ | 24.2 | 20.4 | 2.72 | 12.2 | 14.6 | 0.05 | 1.18 | 10-15 | 14/20 |
| 5 | 6492.T | Okano Valve | MED | ★★★★★ | 21.6 | N/A | 1.77 | 8.2 | 10.1 | 0.05 | 0.41 | 70-80 | 15/20 |
| 6 | 6504.T | Fuji Electric | MED | ★★★ | 20.3 | 17.7 | 2.19 | 11.8 | 10.3 | 0.13 | 1.52 | 10-15 | 13/20 |
| 7 | 5310.T | Toyo Tanso | MED | ★★★★ | 23.2 | 23.8 | 1.30 | 5.7 | 14.6 | 0.06 | 2.42 | 20-30 | 13/20 |
| 8 | 6501.T | Hitachi | MED | ★★★★ | 28.5 | 27.2 | 3.54 | 13 | 11.1 | 0.16 | 0.89 | 3-5 | 12/20 |
| 9 | 6370.T | Kurita Water | MED | ★★★★ | 38.4 | 21.8 | 2.53 | 6.8 | 13.7 | 0.32 | 1.39 | 15-20 | 12/20 |
| 10 | 6302.T | Sumitomo Heavy | MED | ★★★ | 20.6 | 18.8 | 0.92 | 4.7 | 4.8 | 0.37 | 2.83 | 10-15 | 11/20 |
| 11 | 7004.T | Kanadevia | LOW | ★★ | 19.8 | 14.2 | 1.10 | 5.8 | 2.0 | 0.88 | 2.08 | 5-10 | 9/20 |
| 12 | 5406.T | Kobe Steel | LOW | ★★ | 8.7 | 8.5 | 0.59 | 7.2 | 4.8 | 0.65 | 4.14 | 3-5 | 10/20 |
| 13 | 6361.T | Ebara | LOW | ★★★ | 30.9 | 25.4 | 4.49 | 15.8 | 12.1 | 0.43 | 1.34 | 5-8 | 9/20 |
| 14 | 4888.T | Stella Pharma | LOW | ★★ | N/A | N/A | 9.04 | -9.8 | -23.6 | 0.29 | 0 | 90-100 | 9/20 |
Scoring Method
Each stock rated 1-5 on four dimensions (max 20):
- Financial Quality: ROE, margins, balance sheet strength
- Nuclear Purity: % of revenue from nuclear
- Moat Depth: market share, replaceability, switching costs
- Valuation: PE relative to growth, risk/reward
HIGH Conviction — Why These 4
Organo (6368.T) — Score 16/20
Best financials in the group. ROE 23.5%, OpMar 21.4% are exceptional for an industrial. Monopoly on BWR condensate water treatment (IFD technology in ALL BWR plants). 25-30% nuclear exposure is meaningful without being binary. Concern: PB 5.43 and +144% 52w run means premium already priced.
Japan Steel Works (5631.T) — Score 14/20
Strongest moat. ~80% global share in ultra-large nuclear forgings. If Muroran goes offline, Western nuclear new-build stops. Revenue +23% YoY. Concern: PE 32.7x is rich for a cyclical industrial with 10.5% ROE.
IHI (7013.T) — Score 14/20
ROE 23.6% matches Organo. Revenue +23% YoY. Nuclear + aerospace + defense triple exposure. X-energy MOU, NuScale preferred manufacturer. Concern: D/E 1.08 is highest in group, Altman Z 1.88 borderline.
Yokogawa (6841.T) — Score 14/20
Best risk/reward. Fwd PE 20.4x (cheapest HIGH conviction). D/E 0.05 (fortress). Gross margin 46.7% (pricing power). Exclusive DPCS for Rolls-Royce SMR global fleet. Concern: nuclear only 10-15% of revenue.
Changes From Previous DD
| Stock | Previous | Now | Why Changed |
|---|---|---|---|
| Organo | HIGH | HIGH | Confirmed — best financials validate thesis |
| IHI | MEDIUM | HIGH | ROE 23.6% + revenue growth justified upgrade |
| JSW | HIGH | HIGH | Confirmed — moat is world-class |
| Yokogawa | HIGH | HIGH | Confirmed — best risk/reward in group |
| Fuji Electric | HIGH | MEDIUM | Nuclear only 10-15%, power semi is main thesis |
| Okano Valve | HIGH | MEDIUM | Moat is real but micro-cap liquidity risk, +191% already |
| Hitachi | MEDIUM | MEDIUM | Confirmed — too diversified for nuclear conviction |
| Toyo Tanso | HIGH | MEDIUM | ROE 5.7%, FCF negative — moat is real but financials don't yet support HIGH |
| Kanadevia | MEDIUM | LOW | OpMar 2.0%, D/E 0.88 — poor financials |
| Kobe Steel | LOW | LOW | Confirmed — Z-Score 1.78 distress, nuclear 3-5% |
| Ebara | LOW | LOW | Confirmed — semiconductor play, not nuclear |
| Stella Pharma | LOW | LOW | Confirmed — speculative biotech |
Sources
All financial data: StockAnalysis.com (April 2026)
Nuclear exposure estimates: JAIF supplier list, company IR disclosures, segment reports
Moat ratings: market share data from World Nuclear Association, METI, industry reports
REPORT: nuclear_smr_switzerland_2026-04-16.md
Nuclear Theme DD Evolution — European SMR Momentum — 2026-04-16
Time: 01:07
Type: Catalyst-driven DD evolution (European SMR contracts + Swiss ban lift)
Stocks updated: 6841.T, 5631.T, 6501.T
Data sources: GOV.UK, GE Vernova press releases, World Nuclear News, Brussels Signal, New Civil Engineer
Previous data_date: 2026-04-14 → Updated to: 2026-04-16
Executive Summary
Three major European SMR developments in April 2026 strengthen the thesis for Japanese nuclear supply chain stocks:
1. Rolls-Royce SMR / GBE-N Wylfa Contract (Apr 13, 2026) — Landmark UK government contract signed for 3 SMRs at Wylfa, Wales. National Wealth Fund providing up to £599M loan. Moves from planning to active design phase with long lead-time equipment ordering.
2. GVH-AFRY Sweden Collaboration (Apr 7, 2026) — GE Vernova Hitachi Nuclear signed deployment collaboration with AFRY for BWRX-300 in Sweden, including SSM licensing support. Expands European BWRX-300 pipeline beyond Canada/Poland/US.
3. Swiss Council of States Nuclear Ban Lift Vote (Mar 2026) — Upper house voted 27-13 to lift construction ban on new nuclear plants. Goes to National Council next; decision expected by Aug 2026. Long-term catalyst (construction realistically not before 2040) but signals European pro-nuclear shift.
Impact Assessment by Stock
6841.T Yokogawa Electric — MOST DIRECTLY AFFECTED
| Factor | Detail |
|---|---|
| WHY | Yokogawa holds exclusive DPCS contract with Rolls-Royce SMR (Feb 2, 2026). The Apr 13 GBE-N contract moves this from "contract signed" to "active design phase." Long lead-time equipment ordering is now underway. Yokogawa will design, engineer, validate, build, test, install, and commission the main control systems for Wylfa's 3 SMR units. Delivery from UK (Runcorn), Czech Republic, and Netherlands offices. |
| RISK | Nuclear I&C still small share of total revenue in early years. Execution risk on first-of-kind digital control system for SMR. |
| TRIGGER | Watch May 12 earnings for nuclear I&C order book impact. Track Wylfa site preparation milestones and Yokogawa equipment delivery schedule. |
| Thesis status | HOLD — thesis materially strengthened |
Sources:
- GOV.UK: GBE-N and Rolls-Royce SMR sign contract
- Rolls-Royce SMR Wylfa £599M Loan
- Rolls-Royce: Landmark contract announcement
- Yokogawa DPCS contract (Feb 2, 2026)
5631.T Japan Steel Works — STRENGTHENED PIPELINE
| Factor | Detail |
|---|---|
| WHY | JSW holds near-monopoly on ultra-large nuclear-grade forgings (~130 RPVs in service globally). Every new BWRX-300 site requires JSW reactor pressure vessel forgings. European pipeline expanding: GVH-AFRY Sweden deployment, Poland 24-unit program, Swiss ban lift opens potential long-term demand. |
| RISK | European orders are multi-year away from revenue recognition. FCF still negative from capex ramp. Sheffield Forgemasters MOU with GEH for UK-sourced forgings could create competitive pressure (though JSW quality/capacity unmatched). |
| TRIGGER | May 8 earnings for operating CF turnaround. Watch Sweden SSM licensing timeline and Polish BWRX-300 construction schedule. |
| Thesis status | HOLD — thesis strengthened |
Sources:
- GE Vernova/AFRY collaboration announcement
- AFRY/GVH press release
- BWRX-300 supply chain (Power Magazine)
6501.T Hitachi — EUROPEAN EXPANSION CATALYST
| Factor | Detail |
|---|---|
| WHY | Hitachi owns 50% of GE Hitachi Nuclear Energy (GVH). The AFRY collaboration (Apr 7, 2026) brings professional engineering and SSM licensing support for BWRX-300 deployment in Sweden. Combined with existing Darlington (Canada), Poland, and US pipeline, this expands GVH's addressable market. Swiss ban lift adds another potential European customer. |
| RISK | Nuclear is a small sub-segment of the ¥10T Hitachi conglomerate. BWRX-300 revenue won't move the needle meaningfully until mid-2030s. |
| TRIGGER | Watch Swedish SSM pre-licensing progress. Swiss final parliament vote expected Aug 2026. |
| Thesis status | HOLD — thesis strengthened |
Sources:
- GVH-AFRY agreement (World Nuclear News)
- Swiss ban lift vote (Brussels Signal)
- Swiss upper house vote (NucNet)
Stocks NOT Updated (No Direct Impact)
| Ticker | Company | Reason |
|---|---|---|
| 7013.T | IHI Corporation | X-energy/NuScale focus, not Rolls-Royce SMR or BWRX-300 European pipeline |
| 6504.T | Fuji Electric | Domestic radiation monitoring — European SMR deployment does not affect near-term |
| 6368.T | Organo Corp | BWR water treatment is Japan-domestic; European SMRs not yet relevant |
| 6370.T | Kurita Water | Same as Organo — Japan/semiconductor focus |
| 7004.T | Kanadevia | Spent fuel logistics — no connection to European SMR construction |
| 6302.T | Sumitomo Heavy | ITER/BNCT focus — no SMR supply chain exposure |
Switzerland Deep Dive
What happened
- Swiss Council of States voted 27-13 (Mar 2026) to support the federal counterproposal to the "Stop the Blackout" popular initiative
- This would lift the 2018 ban on new nuclear plant construction (enacted after 2017 Energy Strategy 2050 referendum)
- Centre Party's shift was pivotal, voting against a left-wing motion to shelve the proposal
What happens next
- National Council vote required (lower house)
- Decision expected by August 2026
- Referendum likely (Energy Minister Rösti acknowledged this)
- If passed, regulatory framework still needs to be established
Practical implications for Japanese stocks
- Long-term signal, not near-term catalyst: Experts estimate construction not before 2040 even if ban is lifted
- No specific SMR contracts between Swiss entities and GE Hitachi or Rolls-Royce yet
- Major Swiss utilities (Axpo) say ban lift is "symbolic" and does not imply imminent new reactor plans
- Value is directional: Swiss vote joins UK, Sweden, Poland, Czech Republic in European pro-nuclear momentum, expanding the total addressable market for JSW forgings, Yokogawa controls, and Hitachi's GVH JV over the next decade
Sources
- Brussels Signal: Switzerland wants to overturn ban
- NucNet: Swiss upper house backs lifting ban
- SWI swissinfo: Switzerland edges toward lifting ban
- World Nuclear Association: Switzerland profile
Key Dates to Watch
| Date | Event | Stocks Affected |
|---|---|---|
| 2026-05-08 | JSW FY2025 earnings (operating CF turnaround?) | 5631.T |
| 2026-05-09 | Hitachi earnings | 6501.T |
| 2026-05-12 | Yokogawa earnings (nuclear I&C order book) | 6841.T |
| 2026-08-01 | Swiss parliament final vote on nuclear ban lift | 6501.T, 5631.T |
| Mid-2030s | Wylfa SMR operational target | 6841.T |
| End of decade | Darlington BWRX-300 completion | 6501.T, 5631.T |
*Report generated: 2026-04-16*
*Data sources: GOV.UK, GE Vernova, Rolls-Royce SMR, World Nuclear News, NucNet, Brussels Signal, SWI swissinfo, New Civil Engineer*
REPORT: nuclear_smr_switzerland_2026-04-16.md
Nuclear Theme DD Evolution — European SMR Momentum — 2026-04-16
Time: 01:07
Type: Catalyst-driven DD evolution (European SMR contracts + Swiss ban lift)
Stocks updated: 6841.T, 5631.T, 6501.T
Data sources: GOV.UK, GE Vernova press releases, World Nuclear News, Brussels Signal, New Civil Engineer
Previous data_date: 2026-04-14 → Updated to: 2026-04-16
Executive Summary
Three major European SMR developments in April 2026 strengthen the thesis for Japanese nuclear supply chain stocks:
1. Rolls-Royce SMR / GBE-N Wylfa Contract (Apr 13, 2026) — Landmark UK government contract signed for 3 SMRs at Wylfa, Wales. National Wealth Fund providing up to £599M loan. Moves from planning to active design phase with long lead-time equipment ordering.
2. GVH-AFRY Sweden Collaboration (Apr 7, 2026) — GE Vernova Hitachi Nuclear signed deployment collaboration with AFRY for BWRX-300 in Sweden, including SSM licensing support. Expands European BWRX-300 pipeline beyond Canada/Poland/US.
3. Swiss Council of States Nuclear Ban Lift Vote (Mar 2026) — Upper house voted 27-13 to lift construction ban on new nuclear plants. Goes to National Council next; decision expected by Aug 2026. Long-term catalyst (construction realistically not before 2040) but signals European pro-nuclear shift.
Impact Assessment by Stock
6841.T Yokogawa Electric — MOST DIRECTLY AFFECTED
| Factor | Detail |
|---|---|
| WHY | Yokogawa holds exclusive DPCS contract with Rolls-Royce SMR (Feb 2, 2026). The Apr 13 GBE-N contract moves this from "contract signed" to "active design phase." Long lead-time equipment ordering is now underway. Yokogawa will design, engineer, validate, build, test, install, and commission the main control systems for Wylfa's 3 SMR units. Delivery from UK (Runcorn), Czech Republic, and Netherlands offices. |
| RISK | Nuclear I&C still small share of total revenue in early years. Execution risk on first-of-kind digital control system for SMR. |
| TRIGGER | Watch May 12 earnings for nuclear I&C order book impact. Track Wylfa site preparation milestones and Yokogawa equipment delivery schedule. |
| Thesis status | HOLD — thesis materially strengthened |
Sources:
- GOV.UK: GBE-N and Rolls-Royce SMR sign contract
- Rolls-Royce SMR Wylfa £599M Loan
- Rolls-Royce: Landmark contract announcement
- Yokogawa DPCS contract (Feb 2, 2026)
5631.T Japan Steel Works — STRENGTHENED PIPELINE
| Factor | Detail |
|---|---|
| WHY | JSW holds near-monopoly on ultra-large nuclear-grade forgings (~130 RPVs in service globally). Every new BWRX-300 site requires JSW reactor pressure vessel forgings. European pipeline expanding: GVH-AFRY Sweden deployment, Poland 24-unit program, Swiss ban lift opens potential long-term demand. |
| RISK | European orders are multi-year away from revenue recognition. FCF still negative from capex ramp. Sheffield Forgemasters MOU with GEH for UK-sourced forgings could create competitive pressure (though JSW quality/capacity unmatched). |
| TRIGGER | May 8 earnings for operating CF turnaround. Watch Sweden SSM licensing timeline and Polish BWRX-300 construction schedule. |
| Thesis status | HOLD — thesis strengthened |
Sources:
- GE Vernova/AFRY collaboration announcement
- AFRY/GVH press release
- BWRX-300 supply chain (Power Magazine)
6501.T Hitachi — EUROPEAN EXPANSION CATALYST
| Factor | Detail |
|---|---|
| WHY | Hitachi owns 50% of GE Hitachi Nuclear Energy (GVH). The AFRY collaboration (Apr 7, 2026) brings professional engineering and SSM licensing support for BWRX-300 deployment in Sweden. Combined with existing Darlington (Canada), Poland, and US pipeline, this expands GVH's addressable market. Swiss ban lift adds another potential European customer. |
| RISK | Nuclear is a small sub-segment of the ¥10T Hitachi conglomerate. BWRX-300 revenue won't move the needle meaningfully until mid-2030s. |
| TRIGGER | Watch Swedish SSM pre-licensing progress. Swiss final parliament vote expected Aug 2026. |
| Thesis status | HOLD — thesis strengthened |
Sources:
- GVH-AFRY agreement (World Nuclear News)
- Swiss ban lift vote (Brussels Signal)
- Swiss upper house vote (NucNet)
Stocks NOT Updated (No Direct Impact)
| Ticker | Company | Reason |
|---|---|---|
| 7013.T | IHI Corporation | X-energy/NuScale focus, not Rolls-Royce SMR or BWRX-300 European pipeline |
| 6504.T | Fuji Electric | Domestic radiation monitoring — European SMR deployment does not affect near-term |
| 6368.T | Organo Corp | BWR water treatment is Japan-domestic; European SMRs not yet relevant |
| 6370.T | Kurita Water | Same as Organo — Japan/semiconductor focus |
| 7004.T | Kanadevia | Spent fuel logistics — no connection to European SMR construction |
| 6302.T | Sumitomo Heavy | ITER/BNCT focus — no SMR supply chain exposure |
Switzerland Deep Dive
What happened
- Swiss Council of States voted 27-13 (Mar 2026) to support the federal counterproposal to the "Stop the Blackout" popular initiative
- This would lift the 2018 ban on new nuclear plant construction (enacted after 2017 Energy Strategy 2050 referendum)
- Centre Party's shift was pivotal, voting against a left-wing motion to shelve the proposal
What happens next
- National Council vote required (lower house)
- Decision expected by August 2026
- Referendum likely (Energy Minister Rösti acknowledged this)
- If passed, regulatory framework still needs to be established
Practical implications for Japanese stocks
- Long-term signal, not near-term catalyst: Experts estimate construction not before 2040 even if ban is lifted
- No specific SMR contracts between Swiss entities and GE Hitachi or Rolls-Royce yet
- Major Swiss utilities (Axpo) say ban lift is "symbolic" and does not imply imminent new reactor plans
- Value is directional: Swiss vote joins UK, Sweden, Poland, Czech Republic in European pro-nuclear momentum, expanding the total addressable market for JSW forgings, Yokogawa controls, and Hitachi's GVH JV over the next decade
Sources
- Brussels Signal: Switzerland wants to overturn ban
- NucNet: Swiss upper house backs lifting ban
- SWI swissinfo: Switzerland edges toward lifting ban
- World Nuclear Association: Switzerland profile
Key Dates to Watch
| Date | Event | Stocks Affected |
|---|---|---|
| 2026-05-08 | JSW FY2025 earnings (operating CF turnaround?) | 5631.T |
| 2026-05-09 | Hitachi earnings | 6501.T |
| 2026-05-12 | Yokogawa earnings (nuclear I&C order book) | 6841.T |
| 2026-08-01 | Swiss parliament final vote on nuclear ban lift | 6501.T, 5631.T |
| Mid-2030s | Wylfa SMR operational target | 6841.T |
| End of decade | Darlington BWRX-300 completion | 6501.T, 5631.T |
*Report generated: 2026-04-16*
*Data sources: GOV.UK, GE Vernova, Rolls-Royce SMR, World Nuclear News, NucNet, Brussels Signal, SWI swissinfo, New Civil Engineer*
REPORT: nuclear_value_chain_tglass_method_2026-04-21.md
Nuclear Value Chain — T-Glass Method Applied
Time: 10:00
Date: 2026-04-21
Type: Explore — value chain tracing on nuclear theme
Method: T-glass method (trace from global leader backwards, find Japan monopolies)
Result: 9 new companies found, 4 with MONOPOLY positions
Value Chain Map: Nuclear Has 6 Layers (Not 13)
| Layer | What | Japan's Position | Moat |
|---|---|---|---|
| 1. Fuel Cycle | Uranium, enrichment, fuel fab | WEAK (import dependent) | ★ |
| 1b. HTGR Graphite | Fuel pebble material | Toyo Tanso MONOPOLY | ★★★★★ |
| 2. Reactor Components | Forgings, valves, pumps, steel | JSW 80% + Kobe Steel duopoly | ★★★★★ |
| 3. Reactor Systems | I&C, safety, turbines | Yokogawa + MitsubishiE DOMINANT | ★★★★ |
| 4. Construction/EPC | Plant builders | MHI monopoly (Japan PWR) | ★★★★★ |
| 5. Operations | Utilities, water chemistry | Kansai Elec + Organo monopoly | ★★★★ |
| 6. Downstream | Decommission, medicine, fusion | Stella Pharma BNCT monopoly | ★★★★★ |
9 New Companies Found
MONOPOLY Positions (Must Add)
| Ticker | Company | Mkt Cap | Layer | Why |
|---|---|---|---|---|
| 5310.T | Toyo Tanso | ¥121B | Fuel/Materials | ONLY supplier of IG-110 graphite for ALL HTGRs globally. $40M X-energy contract. |
| 6492.T | Okano Valve | ¥16B | Components | Safety relief valve in ALL Japanese BWR plants. Micro-cap = huge leverage to restarts. |
| 4888.T | Stella Pharma | ¥12B | Nuclear Medicine | World's ONLY pharmaceutical-grade BNCT boron drug. |
DOMINANT Positions (Strong Add)
| Ticker | Company | Mkt Cap | Layer | Why |
|---|---|---|---|---|
| 5406.T | Kobe Steel | ¥648B | Components | Only company globally self-sufficient in ALL RPV materials. Duopoly with JSW. |
| 6503.T | Mitsubishi Electric | ¥5.7T | I&C Systems | MELTAC I&C for Holtec SMR-160 + all Japanese nuclear plants. |
STRONG Positions (Good Add)
| Ticker | Company | Mkt Cap | Layer | Why |
|---|---|---|---|---|
| 6361.T | Ebara | ¥1.96T | Components | Nuclear coolant pumps since 1973. NuScale steam compressor partner (Mar 2026). |
| 6965.T | Hamamatsu Photonics | ¥570B | Detection | Global leader in radiation detection sensors. Dual nuclear + medical. |
| 5801.T | Furukawa Electric | ¥740B | Fusion | ITER superconducting cables. SuperPower HTS tape. Tokamak Energy JV. |
| 1963.T | JGC Holdings | ¥485B | EPC | Nuclear waste facility design. NuScale-IHI JV partner. |
Japan's 3 TRUE Nuclear Chokepoints
1. Japan Steel Works (5631.T) — The Most Strategic Single Facility on Earth
JSW's Muroran plant has ~80% global market share in ultra-large nuclear forgings. Their 14,000-ton press handles 670-ton ingots — no other Western-aligned facility can match this. If Muroran goes offline, the ENTIRE Western nuclear new-build program stops. China (CFHI) and Russia (OMZ) have capacity but are geopolitically excluded from Western orders.
2. Toyo Tanso (5310.T) — The Only HTGR Graphite
IG-110 nuclear-grade graphite is used in ALL 3 existing HTGRs globally (Japan HTTR, China HTR-PM, future X-energy Xe-100). No substitute. No second source. Micro-cap (¥121B) with $40M X-energy contract = massive leverage to SMR buildout.
3. Stella Pharma (4888.T) — The Only BNCT Drug
Steboronin is the world's only approved pharmaceutical-grade boron drug for BNCT cancer therapy. Japan is 5+ years ahead of any other country. Micro-cap (¥12B) = speculative but truly unique.
What Japan LACKS in Nuclear
| Gap | Why | Impact |
|---|---|---|
| Uranium mining/enrichment | Zero domestic capacity, 100% import | Geopolitical vulnerability |
| Fuel fabrication | NFI exists but private (Toshiba sub) | No listed pure-play |
| Reactor export track record | Never exported a complete reactor | Korea has (4 APR-1400s to UAE) |
| Gen III+ construction | No new reactor since 2006 (Shika-2) | Skills gap |
Updated Coverage: 12 → 21 Stocks
The T-glass method expanded our nuclear coverage from 12 to 21 stocks, filling gaps in every layer. The biggest gap was Layer 2 (reactor components) where Kobe Steel, Okano Valve, and Toyo Tanso all have monopoly/duopoly positions we were completely missing.
Sources
- JAIF Nuclear Suppliers List Nov 2025
- World Nuclear Association — Heavy Manufacturing
- X-energy/Toyo Tanso graphite agreement
- NuScale/Ebara Elliott partnership Mar 2026
- Mitsubishi Electric/Holtec SMR-160 I&C contract
- Furukawa Electric/Tokamak Energy JV
- Nuclear Reactor Construction Market Report 2026